{"nctId":"NCT00770146","briefTitle":"Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients","startDateStruct":{"date":"2008-11"},"conditions":["Hypercholesterolemia","Coronary Heart Disease"],"count":158,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Mipomersen","type":"EXPERIMENTAL","interventionNames":["Drug: Mipomersen sodium"]}],"interventions":[{"name":"Mipomersen sodium","otherNames":["ISIS 301012","Kynamro™"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of hypercholesterolemia (LDL-C ≥ 100 mg/dL)\n* At high risk of CHD\n* On stable, maximally tolerated statin therapy for 8 weeks\n* On stable, low fat diet for 12 weeks\n* Stable weight for 6 weeks\n\nExclusion Criteria:\n\n* Significant health problems in the recent past including heart attack, stroke, coronary syndrome, unstable angina, heart failure, significant arrhythmia, hypertension, liver disease, cancer, type I diabetes.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point","description":"LDL cholesterol was measured in mg/dL. Samples were taken following an overnight fast. LDL-C was obtained using Friedewald's calculation for patients with triglycerides ≤400 mg/dL and was directly measured by the central laboratory using ultracentrifugation for patients with triglycerides \\>400 mg/dL. The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"24.22"},{"groupId":"OG001","value":"-40.2","spread":"26.85"}]}]}]},{"type":"PRIMARY","title":"Low-density Lipoprotein Cholesterol (LDL-C) at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":"38.6"},{"groupId":"OG001","value":"116","spread":"31.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":"35.1"},{"groupId":"OG001","value":"69","spread":"32.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B at the Primary Efficacy Time Point","description":"Apolipoprotein B was measured in mg/dL. Samples were taken following an overnight fast. The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"18.09"},{"groupId":"OG001","value":"-40.6","spread":"23.59"}]}]}]},{"type":"SECONDARY","title":"Apolipoprotein B at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":"30.1"},{"groupId":"OG001","value":"114","spread":"25.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":"27.2"},{"groupId":"OG001","value":"64","spread":"30.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol at the Primary Efficacy Time Point","description":"Total cholesterol was measured in mg/dL. Samples were taken following an overnight fast. The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"14.58"},{"groupId":"OG001","value":"-26.4","spread":"18.65"}]}]}]},{"type":"SECONDARY","title":"Total Cholesterol at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"200.0","spread":"42.1"},{"groupId":"OG001","value":"202.6","spread":"36.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"192.2","spread":"38.3"},{"groupId":"OG001","value":"147.4","spread":"39.9"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol at the Primary Efficacy Time Point","description":"Non-high-density lipoprotein cholesterol was measured in mg/dL. Samples were taken following an overnight fast. The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"20.43"},{"groupId":"OG001","value":"-38.7","spread":"23.75"}]}]}]},{"type":"SECONDARY","title":"Non-High-Density Lipoprotein Cholesterol at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"144","spread":"44.4"},{"groupId":"OG001","value":"144","spread":"35.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":"38.7"},{"groupId":"OG001","value":"90","spread":"38.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Triglycerides at the Primary Efficacy Time Point","description":"Triglycerides were measured in mg/dL. Samples were taken following an overnight fast. The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"53.26"},{"groupId":"OG001","value":"-26.2","spread":"29.21"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Triglycerides at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":"66.1"},{"groupId":"OG001","value":"143","spread":"65.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"135","spread":"97.5"},{"groupId":"OG001","value":"88","spread":"55.7"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at the Primary Efficacy Time Point","description":"High-density lipoprotein cholesterol (HDL-C) was measured in mg/dL. Samples were taken following an overnight fast. The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"16.44"},{"groupId":"OG001","value":"2.2","spread":"17.99"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"High-Density Lipoprotein Cholesterol at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.4","spread":"15.9"},{"groupId":"OG001","value":"50.8","spread":"12.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.9","spread":"16.1"},{"groupId":"OG001","value":"51.1","spread":"12.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Lipoprotein (a) at the Primary Efficacy Time Point","description":"Lipoprotein (a) was measured in mg/dL. Samples were taken following an overnight fast. The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"28.09"},{"groupId":"OG001","value":"-24.0","spread":"24.47"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Lipoprotein (a) at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":"48.6"},{"groupId":"OG001","value":"54.3","spread":"57.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.5","spread":"47.3"},{"groupId":"OG001","value":"39.6","spread":"47.0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol at the Primary Efficacy Time Point","description":"Very low density lipoprotein (VLDL) cholesterol was measured in mg/dL. Samples were taken following an overnight fast. The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"53.83"},{"groupId":"OG001","value":"-26.7","spread":"28.75"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Very Low Density Lipoprotein Cholesterol at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":"13.2"},{"groupId":"OG001","value":"29","spread":"12.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":"16.3"},{"groupId":"OG001","value":"18","spread":"11.1"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in the Ratio of LDL Cholesterol to HDL Cholesterol at the Primary Efficacy Time Point","description":"The ratio of low-density lipoprotein (LDL) cholesterol to high-density lipoprotein (HDL) cholesterol was measured at Baseline and the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.3","spread":"25.31"},{"groupId":"OG001","value":"-37.4","spread":"27.24"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Ratio of LDL Cholesterol to HDL Cholesterol at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.82","spread":"1.383"},{"groupId":"OG001","value":"2.54","spread":"0.854"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.54","spread":"1.147"},{"groupId":"OG001","value":"1.54","spread":"0.761"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Apolipoprotein A1 at the Primary Efficacy Time Point","description":"Apolipoprotein A1 was measured in mg/dL. Samples were taken following an overnight fast. The primary efficacy time point was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"11.16"},{"groupId":"OG001","value":"-5.6","spread":"12.56"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Apolipoprotein A1 at Baseline and at the Primary Efficacy Time Point","description":"The primary efficacy time point (PET) was the post-baseline visit closest to 14 days after the last dose of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150.8","spread":"30.5"},{"groupId":"OG001","value":"156.8","spread":"25.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"147.8","spread":"27.3"},{"groupId":"OG001","value":"146.8","spread":"24.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":52},"commonTop":["Injection site pain","Injection site erythema","Injection site pruritus","Injection site discolouration","Injection site haematoma"]}}}